BIO MEDICA LABORATORIES LTD.
(FORMERLY BIO MEDICA LABORATORIES PVT. LTD.)

Date: November 13, 2026

To,
NSE Limited,
Department of Corporate Affairs,
Exchange Plaza, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051, Maharashtra, India

Reference: ISIN: INE1BKA01015; Symbol: BMLL

Subject: Outcome of the Meeting of the Board of Directors of Bio Medica Laboratories Limited held on Today i.e. Friday, November 13, 2026.

Dear Sir/Ma'am,

Pursuant to the Regulation 30 and other applicable regulations of the SEBI (Listing obligation & Disclosure requirements) Regulations, 2015 and in continuation of our earlier intimation of Board Meeting dated November 02, 2026 and November 03, 2026, We hereby inform you that the meeting of Board of Directors was duly convened and held at the registered office of the Company i.e. Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Indore-452015 (MP), today i.e., November 13, 2026 at 03:30 P.M. (i.e., 15:30 Hours) and concluded at 04:00 P.M (i.e., 16:00 Hours) the Board of Directors has inter-alia considered and approved the following businesses:

1. Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the half year ended September 30, 2026 in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) 2015.

You are requested to please take the same in your record,

Thanking you
Yours Faithfully

For Bio Medica Laboratories Limited
(Formerly Known as Bio Medica Laboratories Private Limited)

Pradeep Mehta
Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:22:29 +05'30'

Pradeep Mehta
Managing Director
DIN: 07254802

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Limited Review Report on Standalone Unaudited half year ended September 30, 2026 Financial Results of Bio Medica Laboratories Limited ("The Company") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors
Bio Medica Laboratories Limited
Indore (M.P.)

We have reviewed the accompanying standalone statement of unaudited financial results of **Bio Medica Laboratories Limited** ("The Company") for the Half year ended September 30, 2026, attached herewith, The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, Interim Financial Reporting (AS 25) as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed on audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in all material respect in accordance with the applicable recognition and measurement principles laid down in the aforesaid Accounting Standard (AS) prescribed under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the review and significant findings, including any significant deficiencies in internal control that we identify during our review.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration Number: 006719C

CA Sunny Jain
Partner
Membership Number: 429107

Place: Indore
Date; 13.11.2026
UDIN: 26429107FPVDNP7199

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U20293MP2015PLC034576

Reg .Address -Plot no. 11B-11C ,Sector -E Sanwer Road ,Industrial Area ,Indore ,Madhya Pradesh India - 452015

Website - www.biomedica.co.in ,Phone -98272-10008 , 7999274343 ,Email-bmlpl2014@gmail.com

Standalone Statement of Profit and loss for the year ended 30th September 2026

Particulars	For the half year ended 30th September 2026	For the half year ended 31st March 2026	For the half year ended 30th September 2025	For the year ended 31st March 2026
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from operations	1,668.64	1,989.76	1,839.90	3,829.66
II. Other income	57.82	7.37	6.02	13.39
III. Total Income (I + II)	**1,726.46**	**1,997.13**	**1,845.92**	**3,843.04**
IV. Expenses				
Cost of materials consumed	805.95	734.39	884.12	1,618.51
Purchase of stock-in-trade	63.24	32.58	14.62	47.20
Changes in inventories of finished goods work-in-progress and stock in-trade	9.85	-77.23	-65.55	-142.78
Employee benefit expenses	119.43	119.99	114.31	234.30
Finance costs	87.00	130.20	59.62	189.81
Depreciation and amortization expenses	60.83	57.35	34.18	91.53
Other expenses	174.29	122.54	112.53	235.07
Total expenses	**1,320.59**	**1,119.81**	**1,153.83**	**2,273.63**
V. Profit before exceptional and extraordinary items and tax (III - IV)	405.87	877.32	692.09	1,569.41
VI. Exceptional items	-	-	-	-
VII. Profit before extraordinary items and tax (V - VI)	**405.87**	**877.32**	**692.09**	**1,569.41**
VIII. Extraordinary items	-	-	-	-
IX. Profit before tax (VII - VIII)	**405.87**	**877.32**	**692.09**	**1,569.41**
X. Tax expense:				
(1) Current tax	122.06	241.99	175.20	417.18
(2) Deferred tax	-	-10.61	-	-10.61
(3) Short /(Excess) Previous Year Income Tax	-	-	-4.11	-4.11
XI. Profit (Loss) for the period from continuing operations (IX - X)	**283.81**	**645.94**	**521.01**	**1,166.95**
XII. Profit / (loss) from discontinuing operations	-	-	-	-
XIII. Tax expense of discontinuing operations	-	-	-	-
XIV. Profit/(loss) from Discontinuing operations (after tax) (XII - XIII)	**283.81**	**645.94**	**521.01**	**1,166.95**
XV. Profit (Loss) for the period (XI + XIV)	**283.81**	**645.94**	**521.01**	**1,166.95**
XVI. Earnings per equity share				
(1) Basic	2.26	7.04	5.68	12.71
(2) Diluted	2.26	7.04	5.68	12.71

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Pradeep Mehta
Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:14:17 +05'30'

Pradeep Mehta
Managing Director
DIN : 07254802
Place: Indore
Date: 13.11.2026

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN-U20293MP2015PLC034576

Address : Plot no. 11B -11C Sector -E ,Sanwer Road ,Indutrial Area ,Indore ,Madhya Pradesh ,India -452015
Website -www.biomedica.co.in ,Phone no. 98272-10008, 7999274343,Email-bmlpl2014@gmail.com

Notes on Financial Results;

1. The abovementioned Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on **13th November 2026**. The Statutory Auditors have carried out the audit for the half year ended **30th September 2026** and issued unmodified report thereon. These results are available on the Company's Website.

2. The audited financial results of the Company have been prepared in accordance with accounting standards as prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015. The compliance relating to Ind AS is not applicable on the Company since the company got listed on SME platform on NSE.

3. In accordance with Accounting Standard 17 on "Segment Reporting" (AS 17), the Company has only one reportable segment, namely the Medical products Business.

4. Earnings per share are calculated based on the weighted average of the share capital outstanding during the year. The EPS for the half-year/period is not annualized.

5. There are no investor complaints pending as of **September 30,2026**

6. The figures for the previous period/year have been regrouped/reclassified/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/comparable.

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Pradeep Mehta
Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:15:23 +05'30'

Pradeep Mehta
Managing Director
DIN : 07254802
Place: Indore
Date: 13.11.2026

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN-U20293MP2015PLC034576
Address : Plot no. 11B -11C Sector -E ,Sanwer Road ,Indutrial Area ,Indore ,Madhya Pradesh ,India -452015
Website -www.biomedica.co.in ,Phone no. 98272-10008, 7999274343, email-bmlpl2014@gmail.com
Standalone Balance Sheet Statement for the Half Year ended 30th September 2026

Amount (in ₹ Lakhs)

Particulars	As at 30th September 2026	As at 31st March 2026
I. EQUITY AND LIABILITIES		
(1) Shareholder's funds		
(a) Share capital	1257.50	918.00
(b) Reserves and surplus	5907.82	1722.25
(c) Money received against share warrants	–	–
	7165.32	2640.25
(2) Share application money pending allotment	–	–
(3) Non-current liabilities		
(a) Long-term borrowings	361.03	1625.81
(b) Deferred tax liabilities (Net)	–	–
(c) Other long term liabilities	74.00	62.00
(d) Long-term provisions	49.96	38.09
	484.99	1725.90
(4) Current liabilities		
(a) Short-term borrowings	961.83	663.32
(b) Trade payables		
(A) total outstanding dues of micro enterprises and small enterprises; and	109.30	20.29
(B) total outstanding dues of creditors other than micro enterprises and small enterprises	221.17	237.70
(c) Other current liabilities	125.36	133.02
(d) Short-term provisions	101.72	325.36
	1519.37	1379.68
TOTAL	**9169.69**	**5745.83**
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible assets		
(I) Property, Plant and Equipment	620.31	692.27
(ii) Intangible assets	–	–
(iii) Capital work-in-Progress	–	–
(iv) Intangible assets under development	–	–
(b) Non-current investments	–	0.51
(c) Deferred tax assets (net)	30.61	30.61
(d) Long-term loans and advances	743.62	171.97
(e) Other non-current assets	13.45	13.01
	1408.00	908.37
(2) Current assets		
(a) Current investments	–	–
(b) Inventories	3248.25	3330.55
(c) Trade receivables	949.27	907.06
(d) Cash and cash equivalents	2499.23	2.64
(e) Short-term loans and advances	870.46	461.62
(f) Other current assets	194.48	135.60
	7761.69	4837.46
TOTAL	**9169.69**	**5745.83**

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Pradeep Mehta
Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:15:45 +05'30'

Pradeep Mehta
Managing Director
DIN: 07254802
Place: Indore
Date: 13.11.2026

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN-U20293MP2015PLC034576

Address : Plot no. 11B -11C Sector -E ,Sanwer Road ,Indutrial Area ,Indore ,Madhya Pradesh ,India -452015

Website -www.biomedica.co.in ,Phone no. 98272-10008, 7999274343,Email-bmlpl2014@gmail.com

Standalone Cash Flow Statement for the Half Year ended 30th September 2026

Amount (in ₹ Lakhs)

Particulars	For the year ended 30th September 2026	For the year ended 31st March 2026
A. Cash Flow From Operating Activities		
Net Profit before tax and extraordinary items (as per Statement of Profit and Loss)	405.89	1569.41
Adjustments for non Cash/ Non trade items:		
Depreciation & Amortization Expenses	60.83	91.53
Finance Cost	87.00	–
Extra Ordinary item (Prior period gratuity)	–	189.81
(Profit) / Loss on sale of asset	–	1.78
Operating profits before Working Capital Changes	**553.72**	**1852.53**
Adjusted For:		
(Increase) / Decrease in trade receivables	(42.22)	(497.04)
Increase / (Decrease) in trade payables	72.48	(169.77)
(Increase) / Decrease in inventories	82.30	(1516.76)
Increase / (Decrease) in other current liabilities	(7.65)	38.94
Increase / (Decrease) in other long term liabilities	12.00	31.00
Increase / (Decrease) in short term provisions	(223.64)	14.39
Increase / (Decrease) in long term provisions	11.87	6.50
(Increase) / Decrease in Short Term Loans & Advances	(408.84)	290.90
(Increase) / Decrease in Long Term Loans & Advances	(571.65)	(167.96)
(Increase) / Decrease in other current assets	(58.88)	(47.48)
(Increase) / Decrease in other non-current assets	(0.44)	0.43
Cash generated from Operations	**(580.96)**	**(164.32)**
Income Tax (Paid) / Refund	(122.06)	(413.07)
Net Cash flow from Operating Activities(A)	**(703.02)**	**(577.39)**
B. Cash Flow From Investing Activities		
Purchase of tangible assets	(17.92)	(88.16)
Proceeds from sales of tangible assets	29.05	12.05
Receipt of capital subsidy	–	58.10
Investment in subsidiary	0.51	(0.51)
Net Cash used in Investing Activities(B)	**11.64**	**(18.52)**
C. Cash Flow From Financing Activities		
Finance Cost	(87.00)	(189.81)
Increase in / (Repayment) of Short term Borrowings	298.51	170.36
Increase in / (Repayment) of Long term borrowings	(1264.79)	617.33
Increase / (Decrease) in share capital	339.50	–
Security premium received	3901.75	
Net Cash used in Financing Activities(C)	**3187.97**	**597.88**
D. Net Increase / (Decrease) in Cash & Cash Equivalents(A+B+C)	**2496.59**	**1.97**
E. Cash & Cash Equivalents at Beginning of period	2.64	0.68
F. Cash & Cash Equivalents at End of period	2499.23	2.64
G. Net Increase / (Decrease) in Cash & Cash Equivalents(F-E)	**2496.59**	**1.97**

Notes:

1. The Cash Flow Statement has been prepared by Indirect Method as per AS-3 issued by ICAI.
2. Figures of previous year have been rearranged / regrouped wherever necessary
3. Figures in brackets are outflow / deductions

For and on behalf of the Board of Directors

of Bio Medica Laboratories limited

Pradeep Mehta

Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:16:05 +05'30'

Pradeep Mehta

Managing Director

DIN: 07254802

Place: Indore

Date: 13.11.2026

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Limited Review Report on Consolidated Unaudited half year ended September 30, 2026 Financial Results of Bio Medica Laboratories Limited ("The Company") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors
Bio Medica Laboratories Limited
Indore (M.P.)

We have reviewed the accompanying consolidated statement of unaudited financial results of **Bio Medica Laboratories Limited** ("The holding company") and its subsidiary (the holding company and its subsidiary together referred to as "the group") for the Half year ended September 30, 2026, attached herewith, The Statement has been prepared by the holding Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the holding Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, Interim Financial Reporting (AS 25) as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed on audit and accordingly, we do not express an audit opinion.

The statement includes the results of the entities

Name of the entity	**Relationship**
Vitamax Healthcare Private Limited	Subsidiary

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in all material respect in accordance with the applicable recognition and measurement principles laid down in the aforesaid Accounting Standard (AS) prescribed under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the review and significant findings, including any significant deficiencies in internal control that we identify during our review.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration Number: 006719C

VIJAY K. JAIN & ASSOCIATES * CHARTERED ACCOUNTANTS * INDORE M.No. 429107

CA Sunny Jain
Partner
Membership Number: 429107
Place: Indore
Date; 13.11.2026
UDIN: 26429107PEQUFF1858

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U20293MP2015PLC034576
Reg.Address - Plot no.- 11B -11C ,Sector-E Sanwer Road , Industrial Area ,Indore Madhya Pradesh ,India - 452015
Website - www.biomedica.co.in ,Phone No. - 98272-10008 , 7999274343,email-bmlpl2014@gmail.com
Consolidated Unaudited Financial Results For The Half Year September 30,2026

Amount (in ₹ Lakhs)

Particulars	For the half year ended 30th September 2026	For the half year ended 31st March 2026	For the half year ended 30th September 2025	For the year ended 31st March 2026
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from operations	2,160.78	4,308.99	-	4,308.99
II. Other income	58.38	2.32	-	2.32
III. Total Income (I + II)	**2,219.16**	**4,311.31**	**-**	**4,311.31**
IV. Expenses				
Cost of materials consumed	1,107.74	1,847.68	-	1,847.68
Purchase of stock-in-trade	63.24	47.20	-	47.20
Changes in inventories of finished goods work-in-progress and stock in-trade	7.35	-146.60	-	-146.60
Employee benefit expenses	161.88	305.06	-	305.06
Finance costs	122.50	225.62	-	225.62
Depreciation and amortization expenses	70.46	116.34	-	116.34
Other expenses	207.18	290.59	-	290.59
Total expenses	**1,740.35**	**2,685.89**	**-**	**2,685.89**
		-		
V. Profit before exceptional and extraordinary items and tax (III - IV)	478.81	1,625.42	-	1,625.42
VI. Exceptional items	-	-		-
VII. Profit before extraordinary items and tax (V - VI)	**478.81**	**1,625.42**	**-**	**1,625.42**
VIII. Extraordinary items	-	-		-
IX. Profit before tax (VII - VIII)	**478.81**	**1,625.42**	**-**	**1,625.42**
X. Tax expense:		-		
(1) Current tax	138.70	423.33	-	423.33
(2) Deferred tax	-	17.45	-	17.45
(3) Short /(Excess) Previous Year Income Tax	-	-4.11	-	-4.11
XI. Profit (Loss) for the period from continuing operations (IX - X)	**340.11**	**1,188.75**	**-**	**1,188.75**
XII. Profit / (loss) from discontinuing operations	-	-		-
XIII. Tax expense of discontinuing operations	-	-		-
XIV. Profit/(loss) from Discontinuing operations (after tax) (XII - XIII)	**-**	**1,188.75**	**-**	**1,188.75**
XV. Profit (Loss) for the period (XI + XIV)	**340.11**	**1,188.75**	**-**	**1,188.75**
XVI.Less:Minority Interest -Share Of Profit /Loss	**-27.58**	**-10.68**	**-**	**-10.68**
XVII.Profit /Loss For the year	**312.54**	**1,178.07**	**-**	**1,178.07**
XVI. Earnings per equity share				
(1) Basic	565.08	12.95	-	12.95
(2) Diluted	565.08	12.95	-	12.95

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Pradeep Mehta
Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:16:53 +05'30'

Pradeep Mehta
Managing Director
DIN: 07254802
Place: Indore
Date: 13.11.2026

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U20293MP2015PLC034576

Address : Plot no. 11B -11C Sector -E ,Sanwer Road ,Indutrial Area ,Indore ,Madhya Pradesh ,India -452015
Website -www.biomedica.co.in ,Phone no. 98272-10008, 7999274343 ,email -bmpl2014@gmail.com

Notes on Financial Results;

1. The abovementioned Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on**13th November 2026**. The Statutory Auditors have carried out the audit for the half year ended **30th September,2026** and issued unmodified report thereon. These results are available on the Company's Website.
2. The audited financial results of the Company have been prepared in accordance with accounting standards as prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015. The compliance relating to Ind AS is not applicable on the Company since the company got listed on SME platform on NSE.

3. In accordance with Accounting Standard 17 on "Segment Reporting" (AS 17), the Company has only one reportable segment, namely the Medical products Business.

4. Earnings per share are calculated based on the weighted average of the share capital outstanding during the year. The EPS for the half-year/period is not annualized.

5. There are no investor complaints pending as of **30th September 2026**.

6. The figures for the previous period/year have been regrouped/reclassified/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/comparable.

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Pradeep Mehta
Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:17:14 +05'30'

Pradeep Mehta
Managing Director
DIN: 07254802
Place: Indore
Date: 13.11.2026

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U20293MP2015PLC034576

Address : Plot no. 11B -11C Sector -E ,Sanwer Road ,Indutrial Area ,Indore ,Madhya Pradesh ,India -452015
Website -www.biomedica.co.in ,Phone no. 98272-10008, 7999274343 ,email -bmpl2014@gmail.com

Consolidated Balance Sheet Statement for the Half year ended 30th September 2026

Amount (in ₹ Lakhs)

Particulars	As at 30th September 2026 (Unaudited)	As at 31st March 2026 (Audited)
I. EQUITY AND LIABILITIES		
(1) Shareholder's funds		
(a) Share capital	1257.50	918
(b) Reserves and surplus	5735.95	1733.36
(c) Money received against share warrants	– -	
	6993.45	2651.36
Minority Interest	(589.82)	-617.4
(2) Share application money pending allotment	–	
(3) Non-current liabilities		
(a) Long-term borrowings	2034.81	3155.62
(b) Deferred tax liabilities (Net)	– -	
(c) Other long term liabilities	77.28	184.97
(d) Long-term provisions	49.96	38.09
	2162.05	3378.68
(4) Current liabilities	–	
(a) Short-term borrowings	1251.28	843.31
(b) Trade payables		
(A) total outstanding dues of micro enterprises and small enterprises; and	150.01	49.44
(B) total outstanding dues of creditors other than micro enterprises and small enterprises	819.40	507.78
(c) Other current liabilities	161.37	189.36
(d) Short-term provisions	118.20	328.31
	2500.25	1918.2
TOTAL	**11065.93**	7330.84
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible assets		
(I) Property, Plant and Equipment	845.05	1029.3
(ii) Intangible assets	–	
(iii) Capital work-in-Progress	29.75	19.75
(iv) Intangible assets goodwill on acquisition	459.16	671.35
(b) Non-current investments	–	
(c) Deferred tax assets (net)	33.24	33.24
(d) Long-term loans and advances	839.66	89.46
(e) Other non-current assets	20.56	21.11
	2227.42	1864.21
(2) Current assets		
(a) Current investments		
(b) Inventories	3691.82	3636.84
(c) Trade receivables	1465.33	1085.32
(d) Cash and cash equivalents	2510.34	10.35
(e) Short-term loans and advances	901.98	501.73
(f) Other current assets	269.03	232.38
	8838.51	5466.62
TOTAL	**11065.93**	**7330.84**

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Pradeep Mehta
Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:17:34 +05'30'

Pradeep Mehta
Managing Director
DIN:07254802
Place : Indore
Date:13.11.2026

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Consolidated Cash Flow Statement for the year ended 30th September 2026

Amount (in ₹ Lakhs)

Particulars	For the year ended 30th September 2026	For the year ended 31st March 2026
A. Cash Flow From Operating Activities		
Net Profit before tax and extraordinary items (as per Statement of Profit and Loss)	478.82	1625.41
Adjustments for non Cash/ Non trade items:	–	
Depreciation & Amortization Expenses	70.46	116.34
Finance Cost	122.50	225.62
Extra Ordinary item (Prior period gratuity)	–	
(Profit) / Loss on sale of asset	–	1.78
Operating profits before Working Capital Changes	**671.78**	**1969.15**
Adjusted For:		
(Increase) / Decrease in trade receivables	(380.01)	-652.32
Increase / (Decrease) in trade payables	412.19	-5.05
(Increase) / Decrease in inventories	(54.99)	-1790.42
Increase / (Decrease) in other current liabilities	(183.46)	223.52
Increase / (Decrease) in other long term liabilities	(107.69)	153.97
Increase / (Decrease) in short term provisions	(210.11)	17.34
Increase / (Decrease) in long term provisions	11.87	6.5
(Increase) / Decrease in Short Term Loans & Advances	(400.25)	250.88
(Increase) / Decrease in Long Term Loans & Advances	(582.23)	-236.53
(Increase) / Decrease in other current assets	(36.65)	-117.83
(Increase) / Decrease in other non-current assets	0.55	-3.48
Cash generated from Operations	**(859.00)**	**-184.25**
Income Tax (Paid) / Refund	(138.70)	-419.22
Net Cash flow from Operating Activities(A)	**(997.71)**	**-603.46**
B. Cash Flow From Investing Activities		
Purchase of tangible assets	(29.01)	-281.15
Proceeds from sales of tangible assets	132.80	12.05
Receipt of capital subsidy	–	58.1
Investment in subsidiary	0.51 -	
Net Cash used in Investing Activities(B)	**104.30**	**-211**
C. Cash Flow From Financing Activities		
Finance Cost	(122.50)	-225.62
Increase in / (Repayment) of Short term Borrowings	407.97	200.56
Increase in / (Repayment) of Long term borrowings	(1133.32)	848.53
Increase / (Decrease) in share capital	339.50	
Security premium received	3901.75	
Net Cash used in Financing Activities(C)	**3393.40**	823.47
D. Net Increase / (Decrease) in Cash & Cash Equivalents(A+B+C)	**2499.99**	8.52
E. Cash & Cash Equivalents at Beginning of period	10.35	1.82
F. Cash & Cash Equivalents at End of period	2510.34	10.35
G. Net Increase / (Decrease) in Cash & Cash Equivalents(F-E)	**2499.99**	8.52

Notes:

1. The Cash Flow Statement has been prepared by Indirect Method as per AS-3 issued by ICAI.
2. Figures of previous year have been rearranged / regrouped wherever necessary
3. Figures in brackets are outflow / deductions

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Pradeep Mehta
Digitally signed by Pradeep Mehta
Date: 2026.11.13 16:18:05 +05'30'

Pradeep Mehta
Managing Director
Place : Indore
DIN:07254802